Yee, A. J., Mo, C. C., Branagan, A. R., Hartley-Brown, M. A., Lin, J., Mosaheb, K., Oravcova-Mejia, M., Riadi, M., Bobilev, K., Cirstea, D., Puliafito, B., Agyemang, E., Harrington, C. C., Grealish, K., Nicholson, T., Packer, L. R., Richardson, M., Horick, N. K., Richardson, P. G., Raje, N. S. (2026). ISABELA: A phase 2 study of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7562